Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063651 | 0.84 | CA2 (0.36) | — | |
| SCHEMBL3215555 | 0.79 | — | — | |
| SCHEMBL6526686 | 0.75 | PARP1 (0.31) | — | |
| SCHEMBL3114993 | 0.74 | PARP1 (0.43) | — | |
| SCHEMBL2792337 | 0.74 | NCF1 (0.32) | — | |
| SCHEMBL3002690 | 0.74 | PIM1 (0.39) | — | |
| SCHEMBL2794270 | 0.72 | GRM1 (0.31) | — | |
| SCHEMBL1515361 | 0.72 | LOX (0.31) | LOX | |
| SCHEMBL2800956 | 0.72 | GABRP (0.37) | — | |
| SCHEMBL5649760 | 0.72 | PIM1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3621619-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VISCERAL PAIN | Arena Pharmaceuticals, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| CN-110709085-A | Compounds and methods for treating visceral pain | 艾尼纳制药公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-6962993-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050197349-A1 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. | 2005-09-08 | — | — | US | disclosed |
| US-6696567-B2 | INHIBITION OF PROTEIN KINASES OR JANUS KINASE 3; TREATING OR PREVENTING ORGAN TRANSPLANT REJECTION, XENO TRANSPLATION, LUPUS, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS, PSORIASIS, TYPE I DIABETES OR VARIOUS DISEASE COMPLICATIONS | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030220353-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| EP-1294724-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | Pfizer Products Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002000661-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | MAP4K4 3168/4885LOX 639/4885 |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | MAP4K4 2006/4885LOX 2472/4885 |
| US-20030220353-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | MAP4K4 151/4885LOX 2255/4885 |
| US-20050197349-A1 | Pyrrolo[2,3-D]pyrimidine compounds | CDK2, CDK3, JAK3 | MAP4K4 85/4885LOX 2238/4885 |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | MAP4K4 151/4885LOX 2255/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | MAP4K4 2006/4885LOX 2472/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | MAP4K4 2006/4885LOX 2472/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | MAP4K4 3168/4885LOX 639/4885 |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | MAP4K4 2006/4885LOX 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.